Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

SML3515

Sigma-Aldrich

Bulevirtide trifluoroacetate

≥98% (HPLC)

Synonym(s):

Myrcludex B trifluoroacetate, Myrcludex-B trifluoroacetate, N-Tetradecanoylglycyl-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Asp-Phe-Asn-Pro-Asn-Lys-Asp-His-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly-NH2 trifluoroacetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C248H355N65O72 · xC2HF3O2
Molecular Weight:
5398.86 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

(Powder or Lyophilized powder or film)

storage condition

desiccated

color

white to off-white

storage temp.

-10 to -25°C

Biochem/physiol Actions

Bulevirtide is a synthetic lipopeptide derived from the preS1 domain of the Hepatitis B virus (HBV) envelope protein that specifically binds to hepatocytes and efficiently blocks de novo HBV and its satellite virus hepatitis D (HDV) infection both in vitro and in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML3515-VAR:
SML3515-5MG:
SML3515-BULK:
SML3515-25MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Urban S, Neumann-Haefelin C, Lampertico P
Gut, 70, 1782-1794 (2021)
Bulevirtide for HBV and HDV infections
Yardeni D, Koh C
Drugs Today (Barc), 57(7), 433-448 (2021)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service